Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	**Submission Date: 11/01/2022**
Policy Number: PA.CP.PHAR.506	**Effective Date: 10/2020** **Revision Date: 10/2022**
Policy Name: Antithymocyte Globulin (Atgam, Thymoglobulin)	

Type of Submission – Check all that apply:

- ☐ **New Policy**
- ✓ **Revised Policy***
- ☐ **Annual Review - No Revisions**
- ☐ **Statewide PDL -** *Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.*

***All revisions to the policy must be highlighted using track changes throughout the document.**

Please provide any changes or clarifying information for the policy below:

4Q 2022 annual review: no significant changes; references reviewed and updated.

Name of Authorized Individual (Please type or print): **Venkateswara R. Davuluri, MD**	**Signature of Authorized Individual:**

Clinical Policy: Antithymocyte Globulin (Atgam, Thymoglobulin)

Reference Number: PA.CP.PHAR.506
Effective Date: 10/2020
Last Review Date: 10/2022

Revision Log

Description
Antithymocyte globulin (Thymoglobulin®, Atgam®) is an immunoglobulin G.

FDA Approved Indication(s)
Atgam is indicated for:

- The management of allograft rejection in renal transplant patients; when administered with conventional therapy at the time of rejection, Atgam increases the frequency of resolution of the acute rejection episode
- The treatment of moderate-to-severe aplastic anemia in patients unsuitable for bone marrow transplantation.

Limitation(s) of use: The usefulness of Atgam has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi's syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.

Thymoglobulin is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. Thymoglobulin is used in conjunction with concomitant immunosuppression.

Policy/Criteria
Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of PA Health & Wellness® that Atgam and Thymoglobulin are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Kidney Transplant Rejection (must meet all)**:**

1. Member has received or is scheduled for a kidney transplant;
2. If request is for prophylaxis of acute rejection, request is for Thymoglobulin;
3. Prescribed by or in consultation with a nephrologist, transplant specialist, or hematologist/oncologist;
4. Age ≥ 18 years;
5. Dose does not exceed one of the following (a or b):
   a. For Atgam: 15 mg/kg per day;
   b. For Thymoglobulin: 1.5 mg/kg per day.

Approval duration:
7 days for Thymoglobulin for prophylaxis of acute rejection (7 doses)
14 days for Thymoglobulin for treatment of acute rejection (14 doses)
Up to 42 days for Atgam (21 doses)

B. Aplastic Anemia (must meet all)**:**
1. Diagnosis of moderate to severe aplastic anemia;
2. Request is for Atgam;
3. Prescribed by or in consultation with a hematologist;
4. Age ≥ 18 years;
5. Prescribed in combination with cyclosporine;
6. Dose does not exceed 20 mg/kg per day.

Approval duration: Up to 42 days (21 doses)

C. Other diagnoses/indications
1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

II. Continued Therapy

A. All Indications in Section I (must meet all)**:**
1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed (a or b):
   a. For Atgam (i or ii):
      i. For treatment of acute rejection: 15 mg/kg per day;
      ii. For aplastic anemia: 20 mg/kg per day;
   b. For Thymoglobulin for treatment or prophylaxis of acute rejection: 1.5 mg/kg per day.

Approval duration: Up to a total treatment duration of:
7 days for Thymoglobulin for prophylaxis of acute rejection (7 doses)
14 days for Thymoglobulin for treatment of acute rejection (14 doses)
42 days for Atgam (21 doses)

B. Other diagnoses/indications (must meet 1 or 2)**:**
1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.
   Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key
FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives
This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
cyclosporine	**Aplastic Anemia** Adults: 12 mg/kg PO QD Children: 15 mg/kg PO QD	See dosing regimen

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
  - Atgam: patients with a history of a systemic reaction (e.g., anaphylactic reaction) during prior administration of Atgam or any other equine gamma globulin preparation
  - Thymoglobulin:
    - Patients with history of allergy or anaphylactic reaction to rabbit proteins or to any product excipients
    - Patients who have active acute or chronic infections that contraindicate any additional immunosuppression
- Boxed warning(s):
  - Atgam: anaphylaxis
  - Thymoglobulin: immunosuppression

Appendix D: General Information

- The current standard first-line treatment for aplastic anemia is equine antithymocyte globulin (Atgam) combined with cyclosporine (off-label use).

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Antithymocyte globulin (Atgam)	Aplastic anemia	10 to 20 mg/kg IV QD for 8 to 14 days. Additional alternate-day therapy up to a total of 21 doses may be given.	20 mg/kg/dose
Antithymocyte globulin (Atgam)	Treatment of acute renal transplant rejection	10 to 15 mg/kg IV QD for 14 days. Additional alternate-day therapy up to a total of 21 doses may be given.	15 mg/kg/dose
Antithymocyte globulin (Thymogobulin)	Prophylaxis of acute renal transplant rejection	1.5 mg/kg IV QD for 4 to 7 days	1.5 mg/kg/dose

Drug Name	Indication	Dosing Regimen	Maximum Dose
Antithymocyte globulin (Thymogobulin)	Treatment of acute renal transplant rejection	1.5 mg/kg IV QD for 7 to 14 days	1.5 mg/kg/dose

VI. Product Availability

Drug Name	Availability
Antithymocyte globulin (Thymoglobulin)	Vial, powder for solution: 25 mg
Antithymocyte globulin (Atgam)	Ampule: 250 mg/5 mL

VII. References

1. Thymoglobulin Prescribing Information. Cambridge, MA: Genzyme Corporation; April 2020. Available at: http://products.sanofi.us/Thymoglobulin/Thymoglobulin.pdf. Accessed August 26, 2022.
2. Atgam Prescribing Information. New York, NY: Pfizer; August 2021. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=525. Accessed August 26, 2022.
3. Kidney Disease Improving Global Outcomes. KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation 2009; 9 (Suppl 3): Si-S155. doi: 10.1111/j.1600-6143.2009.02834.x
4. Bia M, Adey DB, Bloon RD, Chan L, Kulkarni S, and Tomlanovich S. KDOQI US Commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Kidneys Dis 2010;56:189-218.
5. Schinstock CA, Mannon RB, Budde K, et al. Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation May 2020;104(5):911-22.
6. Cooper JE. Evaluation and treatment of acute kidney rejection in kidney allografts. CJASN March 2020;15:430-8.
7. Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016; 172:187-207.
8. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2019. Available at: http://www.clinicalpharmacology-ip.com/.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J7504	Lymphocyte immune globulin, antithymocyte globulin, equine, parenteral, 250 mg
J7511	Lymphocyte immune globulin, antithymocyte globulin, rabbit, parenteral, 25 mg

Reviews, Revisions, and Approvals	Date
Policy created	10/2020
4Q 2021 annual review: no significant changes; references reviewed and updated.	10/2021

Reviews, Revisions, and Approvals	Date
4Q 2022 annual review: no significant changes; references reviewed and updated.	10/2022